MX2018012018A - Composicion para el tratamiento de la distrofía muscular de duchenne. - Google Patents

Composicion para el tratamiento de la distrofía muscular de duchenne.

Info

Publication number
MX2018012018A
MX2018012018A MX2018012018A MX2018012018A MX2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A
Authority
MX
Mexico
Prior art keywords
muscular dystrophy
treatment
composition
duchenne muscular
asds
Prior art date
Application number
MX2018012018A
Other languages
English (en)
Inventor
Horne Graeme
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1605383.7A external-priority patent/GB201605383D0/en
Priority claimed from GBGB1612920.7A external-priority patent/GB201612920D0/en
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2018012018A publication Critical patent/MX2018012018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen dispersiones sólidas amorfas (asd) que comprenden el compuesto 5-(etilsulfonil)-2-(naftalen-2-il)venzo[d]oxasol (ezutromid) y un polímero. Los ASDs encuentran aplicación en el tratamiento o la profilaxis de la distrofia muscular de Duchene y distrofia muscular de Becker.
MX2018012018A 2016-03-30 2017-03-29 Composicion para el tratamiento de la distrofía muscular de duchenne. MX2018012018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1605383.7A GB201605383D0 (en) 2016-03-30 2016-03-30 Composition for the treatment of duchenne muscular dystrophy
GBGB1612920.7A GB201612920D0 (en) 2016-07-26 2016-07-26 Composition for the treatment of Duchenne Muscular Dystrophy
PCT/GB2017/050884 WO2017168151A1 (en) 2016-03-30 2017-03-29 Composition for the treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2018012018A true MX2018012018A (es) 2019-07-04

Family

ID=58640913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012018A MX2018012018A (es) 2016-03-30 2017-03-29 Composicion para el tratamiento de la distrofía muscular de duchenne.

Country Status (11)

Country Link
US (1) US20200016076A1 (es)
EP (1) EP3500245A1 (es)
JP (1) JP2019510056A (es)
KR (1) KR20190026647A (es)
CN (1) CN109803641A (es)
AU (1) AU2017243198A1 (es)
BR (1) BR112018070076A2 (es)
IL (1) IL262013A (es)
MX (1) MX2018012018A (es)
PH (1) PH12018502276A1 (es)
WO (1) WO2017168151A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
NZ570625A (en) 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
KR102182889B1 (ko) * 2013-05-06 2020-11-25 리젠츠 오브 더 유니버시티 오브 미네소타 당을 포함하는 양친매성 공중합체
GB201412010D0 (en) * 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia

Also Published As

Publication number Publication date
JP2019510056A (ja) 2019-04-11
EP3500245A1 (en) 2019-06-26
WO2017168151A1 (en) 2017-10-05
US20200016076A1 (en) 2020-01-16
AU2017243198A1 (en) 2018-11-22
IL262013A (en) 2018-12-31
PH12018502276A1 (en) 2019-09-09
CN109803641A (zh) 2019-05-24
BR112018070076A2 (pt) 2019-05-21
KR20190026647A (ko) 2019-03-13

Similar Documents

Publication Publication Date Title
EP3191533A4 (en) Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof
EP3220741A4 (en) Composition and kits for inhibition of pathogenic microbial infection and methods of using the same
EP3428196A4 (en) ORGANIC SILICON COMPOUND, AND RUBBER COMPOUNDING AGENT AND RUBBER COMPOSITION THEREWITH
CL2018002697A1 (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos.
EP3160278A4 (en) Glove having durable ultra-thin polymeric coating
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
EP3190100A4 (en) Polymerizable compound, polymer, polymerizable composition, and film
EP3106478A4 (en) Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body
EP3275916A4 (en) Polymer, oxidized polymer, polymer composition, gel-type polymer composition, and use thereof
HK1231466A1 (zh) 用於治疗病毒感染的异吲哚啉衍生物
EP3161043A4 (en) Modified fillers for rubber compounding and masterbatches derived therefrom
EP3124511A4 (en) Nitrile group-containing copolymer rubber, crosslinkable rubber composition and crosslinked rubber product
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
EP3530092A4 (en) DIRECT SEED METHOD DEVICE FOR RICE FIELDS
EP3269768A4 (en) Nitrile rubber composition and crosslinked rubber product
SG10201901705RA (en) High torque polymer fittings
MX2015017037A (es) Composiciones y metodos para tratar el cabello.
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
EP3299398A4 (en) Copolymer for use as polymer blend compatibilizer, and resin composition
EP3113767A4 (en) Mtor-independent activator of tfeb for autophagy enhancement and uses thereof
PH12018502276A1 (en) Composition for the treatment of duchenne muscular dystrophy
EP3102169A4 (en) Dispersions of superabsorbent polymers, processing thereof and articles formed from the dispersions
EP3495406A4 (en) ACTIVE TARGETING TYPE POLYMER DERIVATIVE, COMPOSITION CONTAINING SAID POLYMER DERIVATIVE, AND USES OF SAID POLYMER DERIVATIVE AND COMPOSITION THEREOF
GB201208178D0 (en) Pharmaceutical composition for the treatment of duchenne muscular dystrophy
EP3255065A4 (en) Modified conjugated diene-based polymer and rubber composition containing same